Persistent Asset Partners Ltd Has $1.42 Million Position in Johnson & Johnson $JNJ

Persistent Asset Partners Ltd lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 58.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,605 shares of the company’s stock after selling 7,988 shares during the period. Persistent Asset Partners Ltd’s holdings in Johnson & Johnson were worth $1,424,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of JNJ. Plato Investment Management Ltd lifted its position in Johnson & Johnson by 3.9% during the 2nd quarter. Plato Investment Management Ltd now owns 72,416 shares of the company’s stock worth $18,284,000 after acquiring an additional 2,743 shares during the last quarter. Hexagon Capital Partners LLC increased its stake in shares of Johnson & Johnson by 5.3% in the second quarter. Hexagon Capital Partners LLC now owns 5,167 shares of the company’s stock worth $1,312,000 after purchasing an additional 261 shares during the period. Prospect Financial Group LLC lifted its position in shares of Johnson & Johnson by 3.1% during the 2nd quarter. Prospect Financial Group LLC now owns 2,344 shares of the company’s stock worth $595,000 after purchasing an additional 70 shares during the last quarter. Roman Butler Fullerton & Co. boosted its stake in Johnson & Johnson by 0.7% during the 2nd quarter. Roman Butler Fullerton & Co. now owns 11,481 shares of the company’s stock valued at $2,959,000 after purchasing an additional 83 shares during the period. Finally, Simplicity Wealth LLC grew its holdings in Johnson & Johnson by 69.7% in the 2nd quarter. Simplicity Wealth LLC now owns 53,196 shares of the company’s stock valued at $13,510,000 after buying an additional 21,844 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.0%

Shares of JNJ opened at $268.30 on Friday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a market cap of $646.58 billion, a PE ratio of 31.09, a PEG ratio of 2.56 and a beta of 0.24. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $276.47. The stock has a 50 day simple moving average of $258.88 and a 200-day simple moving average of $243.94.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same period in the prior year, the business posted $2.77 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s payout ratio is currently 62.11%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Morgan Stanley upped their price target on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. TD Cowen raised their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price for the company in a research note on Wednesday, May 13th. Finally, Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $268.22.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved J&J’s oral psoriasis pill, Icotyde, expanding the company’s immunology portfolio and giving it a simpler treatment option to compete with rival products from Bristol Myers Squibb and AbbVie. The pill could also broaden J&J’s presence in China, although it may compete with the company’s established injectable Tremfya franchise. China approves J&J’s oral psoriasis pill
• Positive Sentiment: The FDA expanded approval of Imaavy for warm autoimmune hemolytic anemia in patients 12 and older who are receiving or have previously received steroids. As the first approved treatment for this rare, potentially life-threatening disorder, Imaavy addresses an unmet need and could support J&J’s rare-disease growth strategy. Imaavy expands into rare blood disorder
• Positive Sentiment: Recent analysis points to a favorable shift in J&J’s product mix, with newer products increasingly offsetting pressure from the STELARA patent loss. This supports the view that growth in the broader Innovative Medicine portfolio may be more important than the shrinking contribution from STELARA. Did a product swap fuel JNJ stock’s surge?
• Positive Sentiment: Investors continue to view JNJ as a defensive dividend holding, supported by its balance sheet, diversified healthcare operations and ability to generate dependable returns through economic cycles. Johnson & Johnson is a top dividend stock

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 63,972 shares of company stock worth $16,245,605 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.